KDM4C and esophageal squamous cell carcinoma: Currently, a clinical trial evaluating caffeic acid as a JMJD2C modulator is being carried out in China, with the aim to investigate the efficacy and safety of caffeic acid in the treatment of advanced ESCC in China.